Drug-Eluting Stents: Is the Tide Turning?

Registry data suggest that DES recipients may fare better than BMS recipients after all.

The use of drug-eluting stents (DES) in percutaneous coronary intervention has fallen dramatically in the past 1 to 2 years, following reports of late stent thrombosis and increased mortality associated with off-label placement (JW Cardiol May 23 2007). Two new studies of registry data from the New York State PCI Reporting System explore real-world experience with DES and bare-metal stents (BMS).

In the first study, 772 patients with ST-segment-elevation MI treated within 12 hours with BMS were compared with 1154 such patients treated with DES. Baseline characteristics were similar in the two groups. A nonsignificant trend toward lower risk-adjusted in-hospital mortality was seen in DES recipients (1.4%), compared with BMS recipients (2.4%).…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI